La investigación al frente del SARS-COV-2 y la COVID-19 en el departamento de enfermedades infecciosas del Hospital Universitario San Pedro-CIBIR
DOI:
https://doi.org/10.66737/ier.zub.276Palabras clave:
SARS-CoV-2, COVID-19, Pandemia, investigación, enfermedades infecciosasResumen
Durante la pandemia provocada por el SARS-CoV-2, agente causal de la COVID-19, el Departamento de Enfermedades Infecciosas en su brazo armado o asistencial del Hospital y en su lado más científico en el Centro de Investigación Biomédica han puesto su grano de arena para dar luz a la generación de conocimiento práctico y básico necesarios para conseguir salir de la gran crisis generada. En este artículo se enumeran las diferentes aportaciones publicadas por los miembros de este equipo multidisciplinar.
Descargas
Referencias
Berastegui-Cabrera, J., Salto-Alejandre, S., Valerio, M., Pérez-Palacios, P., Arnaiz-De Las Revillas, F., Abelenda-Alonso, G., ... & Sánchez-Céspedes, J. (2021). SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load. Journal of Infection, 82(3), e38-e41. Berastegui-Cabrera, J. et al., (2021). SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load. J Infect, 82:e38-e41.1.
Blanco, J. R., Cobos-Ceballos, M. J., Navarro, F., Sanjoaquin, I., de Las Revillas, F. A., Bernal, E., ... & Ugedo, J. (2021). Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clinical Microbiology and Infection, 27(6), 892-896. Blanco, J.R. et al., (2021). Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clin Microbiol Infect, 27:892-896. ConPlas-19 (2021). Disponible en: https://eu-isciii.es/covidfundinspain/multicenter-randomized-clinical-trial-of-convalescent-plasma-therapy-versusstandard-of-care-for-the-treatment-of-covid-19-in-hospitalized-patients/
Consorcio “Scourge” Determinantes genéticos y biomarcadores genómicos de riesgo en pacientes con infección por coronavirus Sars-CoV-2”. Disponible en: https://www.scourge-covid.org
COVID-19@Spain and COVID@HULP Study Groups (2021). Development and validation of a prediction model for 30-day mortality in hospitalized patients with COVID-19: the COVID-19 SEIMC score. Thorax, 76:920-929.
Cuervo, G., de Alarcón, A., Sousa, D., Barca, L. V., Fernández-Hidalgo, N., Gutiérrez-Carretero, E., ... & Acevedo, M. R. (2021). Impact of the COVID-19 pandemic on the diagnosis, management and prognosis of infective endocarditis. Clinical Microbiology and Infection, 27(4), 660-664. Escolà-Vergé, L. et al., (2021).. Cuervo G, de Alarcón A, Sousa D, Barca LV, Fernández-Hidalgo N, et al.,. Impact of the COVID-19 pandemic on the diagnosis, management and prognosis of infective endocarditis. Clin Microbiol Infect, 27:660-4.
Del Amo, J., Polo, R., Moreno, S., Díaz, A., Martínez, E., Arribas, J. R., ... & for The Spanish HIV/COVID-19 Collaboration*. (2020). Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Annals of internal medicine, 173(7), 536-541.The Spanish HIV/COVID-19 Collaboration (2020). Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med, 173:536-41.
Gutiérrez-Gutiérrez, B., Del Toro, M. D., Borobia, A. M., Carcas, A., Jarrín, I., Yllescas, M., ... & Escudero, E. M. (2021). Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. The Lancet infectious diseases, 21(6), 783-792.REIPI-SEIMC COVID-19 group and COVID@HULP groups (2021). Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. Lancet Infect Dis, 21:783-792.
Íñiguez, M., Pérez-Matute, P., Villoslada-Blanco, P., Recio-Fernandez, E., Ezquerro-Perez, D., Alba, J., ... & Oteo, J. A. (2021). ACE gene variants rise the risk of severe COVID-19 in patients with hypertension, dyslipidemia or diabetes. A pilot study. medRxiv. Íñiguez, M. et al., (2021). ACE gene variants rise the risk of severe COVID-19 in patients with hypertension, dyslipidemia or diabetes. A pilot study. Front Endocrinol (Lausanne). 12:688071. doi: 10.3389/fendo.2021.688071. eCollection 2021.
Ochoa-Callejero, L., García-Sanmartín, J., Villoslada-Blanco, P., Íñiguez, M., Pérez-Matute, P., Pujadas, E., ... & Martínez, A. (2021). Circulating levels of calcitonin gene-related peptide are lower in COVID-19 patients. Journal of the Endocrine Society, 5(3), bvaa199. Ochoa-Callejero, L. et al., (2021a). Circulating levels of calcitonin gene-related peptide are lower in COVID-19 patients. J Endocr Soc 4, 5(3):bvaa199.
Ochoa-Callejero, L., García-Sanmartín, J., Villoslada-Blanco, P., Íñiguez, M., Pérez-Matute, P., Pujadas, E., ... & Martínez, A. (2021). Circulating levels of calcitonin gene-related peptide are lower in COVID-19 patients. Journal of the Endocrine Society, 5(3), bvaa199.Ochoa-Callejero, L. et al., (2021b). Response to Letter to the Editor form Anis Abobaker. Circulating levels of calcitonin gene-related peptide are lower in COVID-19 patients. J Endocr Soc 17, 5(10):bvab053.
OSCAR (2021). Disponible en: https://clinicaltrials.gov/ct2/show/NCT04376684
Oteo, J. A., Marco, P., de León, L. P., Roncero, A., Lobera, T., & Lisa, V. (2020). A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with moderate disease. A strategy associated with a reduction in hospital admissions and complications. medRxiv.Oteo, J.A. et al., (2020a). A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with moderate disease. A strategy associated with a reduction in hospital admissions and complications. Disponible en: https://www.medrxiv.orgcontent/10.1101/2020.06.10.20101105v1
Oteo, J.A. et al., (2020b). Characteristics and prevalence of pneumococal pneumonia infection in COVID-19 patients. ESCMID Conference on Coronavirus Disease (ECCVID). On line, 23-25 september 2020. Disponible en: https://www.eccvid.org/video-liste.php?p=29&&c=&t=&f=&a=&vt=& coday=&cotype=&coref=&coroom=&tri=&noCarousel=&nc=
Rodríguez-Baño, J., Pachón, J., Carratalà, J., Ryan, P., Jarrín, I., Yllescas, M.,... & Ruiz, J. P. (2021). Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clinical Microbiology and Infection, 27(2), 244-252.SAM-COVID Study Group (2021). Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clin Microbiol Infect, 27:244-52.
Ruiz-Arrondo, I., Portillo, A., Palomar, A. M., Santibáñez, S., Santibáñez, P., Cervera, C., & Oteo, J. A. (2021). Detection of SARS-CoV-2 in pets living with COVID-19 owners diagnosed during the COVID-19 lockdown in Spain: A case of an asymptomatic cat with SARS-CoV-2 in Europe. Transboundary and emerging diseases, 68(2), 973-976. Ruiz-Arrondo, I. et al., (2020). Detection of SARS-CoV-2 in pets living with COVID-19 owners diagnosed during the COVID-19 lockdown in Spain: A case of an asymptomatic cat with SARS-CoV-2 in Europe. Transbound Emerg Dis, 68:973-6.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2022 José Oteo, Jorge Alba, José Blanco, Cristina Cervera, Lara García Álvarez, Concepción García-García, Valvanera Ibarra, María Iñiguez, Luis Metola, Sonia Omatos, Ana María Palomar, Galadriel Pellejero, Laura Pérez-Martínez, Patricia Pérez-Matute, Aranzazu Portillo, Emma Recio-Fernández, Lourdes Romero, Ignacio Ruiz-Arrondo, Paula Santibáñez, Sonia Santibáñez, Mercedes Sanz, Pablo Villoslada-Blanco (Autor/a)
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Los autores que publican en Zubía conservan los derechos de autor de sus trabajos y autorizan a la revista la primera publicación de los mismos.
Los artículos se publican bajo la licencia Creative Commons Atribución–No Comercial–Compartir Igual (CC BY-NC-SA), que permite su uso, distribución y reproducción en cualquier medio, siempre que se cite adecuadamente la autoría original, no se realice un uso comercial y se mantenga la misma licencia.
